ReviewCardiovascular research2020
The pathogenic role of coronary microvascular dysfunction in the setting of other cardiac or systemic conditions.
Review in Cardiovascular research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 82 citations in OpenAlex.
- Kinetic modeling with total body PET-current status and future applications.The British journal of radiology · 2026Review
- Covert macrovascular disease and early outcome after ischemic cerebrovascular events.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Observational
- Coronary Microvascular Dysfunction: Epidemiology, Pathophysiology, Diagnosis, and Treatment.MedComm · 2026Review
- Diagnostic performance of angiography-derived IMR for coronary microcirculation disease assessment in INOCA patients.Cardiology journal · 2026Article
- Ultrasound Renal Stress Test Assessment in Moderate-to-Severe Psoriasis: A Pilot Study.Psoriasis (Auckland, N.Z.) · 2026Article
- Iron-dependent ferroptosis in cardiac microvascular endothelial cells: a key link between dysregulated iron homeostasis and microcirculatory injury during myocardial ischemia-reperfusion.Frontiers in cardiovascular medicine · 2026Review
- Association between the C-reactive protein-triglyceride-glucose index and the presence and prognosis of coronary microvascular dysfunction in patients with chronic coronary syndrome.Frontiers in cardiovascular medicine · 2026Article
- Association of the C-reactive protein-triglyceride glucose index with microvascular obstruction and long-term prognosis in patients with acute myocardial infarction: a CMR-based study.Frontiers in endocrinology · 2026Observational
- Chronic Kidney Disease, Circulating Ceramides, and Coronary Microvascular Dysfunction: Insights from the CRUISE-MET Study.Cardiorenal medicine · 2026Observational
- Effects of metabolic syndrome and its components on myocardial microcirculation in obstructive coronary artery disease patients: a CMR perfusion study.Cardiovascular diabetology · 2025Article
- Advances in the diagnosis and management of post-percutaneous coronary intervention coronary microvascular dysfunction: Insights into pathophysiology and metabolic risk interactions.World journal of cardiology · 2025Review
- Epicardial Fat Tissue: A Potential Marker for Coronary Microvascular Dysfunction.Journal of the American Heart Association · 2025Article
- The comprehensive effects of high-sensitivity C-reactive protein and triglyceride glucose index on cardiometabolic multimorbidity.Frontiers in endocrinology · 2025Article
- Self-reported health as a predictor of cardiometabolic multimorbidity in Chinese older adults: a national cross-sectional study.Frontiers in public health · 2025Article
- Associations Between the Atherogenic Index of Plasma and Triglyceride-Glucose Index With Coronary Microvascular Dysfunction in Hypertensive Patients.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- Endothelial Cell-Specific Prolyl Hydroxylase-2 Deficiency Augments Angiotensin II-Induced Arterial Stiffness and Cardiac Pericyte Recruitment in Mice.Journal of the American Heart Association · 2024Article
- Article
- Obesity: the perfect storm for heart failure.ESC heart failure · 2024Review
- Myocardial perfusion improvement and mechanism after percutaneous intramyocardial septal radiofrequency ablation in obstructive hypertrophic cardiomyopathy: a study of myocardial contrast echocardiography.The international journal of cardiovascular imaging · 2024Article
- Coronary microvascular dysfunction in childhood: An emerging pathological entity and its clinical implications.American heart journal plus : cardiology research and practice · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronary microvascular dysfunction (CMD) plays a pathogenic role in cardiac and systemic conditions other than microvascular angina. In this review, we provide an overview of the pathogenic role of CMD in the setting of diabetes mellitus, obesity, hypertensive pregnancy disorders, chronic inflammatory and autoimmune rheumatic disorders, chronic kidney disease, hypertrophic cardiomyopathy, and aortic valve stenosis. In these various conditions, CMD results from different structural, functional, and/or dynamic alterations in the coronary microcirculation associated with the primary disease process. CMD is often detectable very early in the course of the primary disease, before clinical symptoms or signs of myocardial ischaemia are present, and it portrays an increased risk for cardiovascular events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.